CSE | FSE

novamentis life science

Strategic Investing

A Canadian-based public company that builds and supports a diversified portfolio of health and wellness businesses. Aiming to be an industry leader in the development of objective biologic endpoints to validate subjective behavioral changes in people receiving psychedelic therapy.

 

Our Holdings

novamentis biotech

Nova Mentis Biotech

Wholly owned subsidiary investigating medicinal psychedelics. Current focus indications: obesity, diabetes, liver disease (NASH)

Learn More


Pilz BioScience

Pilz Bioscience

Wholly owned subsidiary investigating medicinal psychedelics. Current focus indications: Autism Spectrum Disorder

Learn More

Nova Mentis Life Science
Stock Performance

CSE FSE

Latest News

Nova Mentis Expands Pre-Clinical Development Pipeline;
Company Begins Fragile X Syndrome Treatment with its Proprietary Psilocybin Drug

Vancouver, British Columbia – February 18 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCQB: LIBFF) (“NOVA” or the “Company”), a leader in the development of serotonergic psychedelic compounds, is pleased to announce that the Company is expanding its pre-clinical program to develop a novel diagnostic and treatment approach to fragile X syndrome (FXS) ...

Nova Mentis Appoints Gary R. Harlem to Scientific Advisory Board

Vancouver, British Columbia – February 11, 2021 – Nova Mentis Life Science Corp. (CSE: NOVA) (FSE: HN3Q) (OTCPK: LIBFF) (“NOVA” or the “Company”), a leader in the development of serotonergic psychedelic compounds, is pleased to announce that it has appointed Gary R. Harlem to its Scientific Advisory Board, effective immediately. Mr. Harlem is the founder and CEO of Altucell Biotech, a cellular engineering and biotech company focused on fulfilling a large "unmet need" in cell, molecular and ...